Introduction {#s1}
============

Severe acute asthma (SAA; status asthmaticus) is a severe and potentially fatal asthma exacerbation that does not respond to standard treatment with bronchodilators and systemic corticosteroids \[[@C1]\]. Every child with asthma is at risk of SAA, even those with mild asthma \[[@C2], [@C3]\]. Admission to a paediatric intensive care unit (PICU) occurs in 5--34% of all asthma hospitalisations \[[@C4]--[@C7]\]. Worldwide, the number of children requiring PICU admission increased markedly in the past decade, while the prevalence of asthma in children did not \[[@C4], [@C5], [@C8], [@C9]\]. Previously, we showed a three-fold increase of children with SAA admitted to Dutch PICUs between 2003 and 2013, with a significant increase over the years in the proportion of steroid-naïve children \[[@C9]\].

New asthma guidelines \[[@C10]\] advise clinicians to look for key triggers that put patients at an increased risk of an exacerbation \[[@C11]\]. Multiple studies have focused on risk factors for PICU admission, with different outcomes. Those risk factors included inhaled corticosteroids (ICS) use \[[@C2], [@C7], [@C12]\], longer asthma duration \[[@C13]\], sex \[[@C7], [@C12]\], ethnicity \[[@C2]\], previous emergency department visits \[[@C13]\] or (PICU) hospitalisations \[[@C2], [@C14], [@C16]--\], sensitisation to (multiple) aeroallergens \[[@C13], [@C15]\] and exposure to environmental tobacco smoke (ETS) \[[@C14]\].

In contrast to the above studies, we included all these risk factors in this multicentre (including all Dutch PICUs) prospective study. Identifying risk factors offers the opportunity for early intervention to avoid PICU admission of children with SAA. Since daily ICS is the most effective treatment to reduce asthma symptoms and prevent exacerbations \[[@C1], [@C17]--[@C20]\], we hypothesised that children without daily ICS are more prone to SAA requiring PICU admission. In addition, we looked into other risk factors such as ETS, viral infections, lower socioeconomic status (SES), sensitisation to (multiple) aeroallergens, and previous asthma-related healthcare visits.

Methods {#s2}
=======

We prospectively identified all children (aged 2--18 years) with SAA admitted to all seven Dutch academic PICUs or one of the paediatric wards of four participating general hospitals between 2016 and 2018. The four general hospitals were recruited based on geographical distribution over the Netherlands and needed to have a staff paediatric pulmonologist. Furthermore, these hospitals were good examples of general hospitals in the Netherlands, enhancing the external validity of the study. We included children aged ≥2 years, since SAA treatment is the same for children across all age ranges in the Netherlands. For each group (PICU and general ward), patients were recruited until the pre-planned sample size of 110 patients per group had been achieved. SAA was defined as a doctor-diagnosed asthma exacerbation requiring systemic corticosteroids and hospital admission. According to Dutch national guidelines, all children receive the same initial treatment: oxygen, continuous inhalation with salbutamol plus ipratropium and systemic corticosteroids \[[@C21]\]. When the asthma score, as developed by Q[ureshi]{.smallcaps} *et al.* \[[@C22]\], is still ≥10 after three consecutive nebulisations with salbutamol plus ipratropium an intravenous magnesium sulphate bolus is administered. If continued nebulisation and *i.v.* magnesium sulphate lead to insufficient response, continuous infusion with salbutamol is started. When *i.v.* salbutamol is administered, children are transferred to a PICU, regardless of the dosage. Evidence indicates that this protocol is well followed in the Netherlands \[[@C9]\]. A child was classified as steroid-naïve when there was no maintenance treatment with ICS for \>7 days before admission. The highest educational level of the parents and the postal code were used to determine SES. Ethnicity was defined as Caucasian or non-Caucasian. The severity of the exacerbation at the time of admission was classified using the Asthma Score. Additional details on the definition of SES, ethnicity and the Dutch guidelines for PICU admission are provided in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials).

Adherence to ICS was expressed as the proportion of days covered (PDC) in the period preceding the index admission \[[@C23]\], according to the pharmacy records. Continuous and categorical measures of ICS adherence were used. For the categorical measures a PDC of \<80% (non-adherent) or a PDC ≥80% (adherent) were used. The cut-off values were chosen based on previous studies \[[@C24], [@C25]\].

We assessed a radioallergosorbent test for inhaled allergens in all children unless performed within the previous year. From every child, we acquired a nasal swab within 24 h after admission. The nasal swab was examined using real-time reverse transcriptase (RT)-PCR for the detection of viruses \[[@C26]\].

We determined urinary cotinine within 6 h after admission, as a proxy for ETS \[[@C27]\]. A value of \<10 ng·mL^−1^ was interpreted as no recent ETS exposure; a value of 10--100 ng·mL^−1^ as second-hand smoke exposure; and a value \>200 ng·mL^−1^ as active smoking \[[@C28]\].

A blood sample for DNA analysis was only collected if blood was drawn for standard care measurements. DNA was isolated from 200 μL of whole blood. Single nucleotide polymorphisms (SNPs) in the *ADRβ2* at position 16 (rs1042713) and 27 (rs1042714), and SNPs in the CDHR3 (rs6967330) were characterised \[[@C29]\]. Further details on the methods for medication adherence and viral detection are provided in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials). Information about patient history, SES and environmental triggers was obtained from patients and caregivers using a web-based questionnaire, using LimeSurvey (version 2.06lts; [www.limesurvey.org/](www.limesurvey.org/)).

Analyses {#s2a}
--------

Data are presented as mean±[sd]{.smallcaps} or median (interquartile range). The Chi-squared test was used to compare categorical variables between both groups, and the Mann--Whitney test was used for continuous variables. Multivariate analysis was performed using multiple logistic regression analysis to evaluate the relationship between covariates and the probability of PICU admission.

Covariates were chosen based on the univariate analysis. Additional details on the sample size calculation and analyses are provided in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials). Given the potential difference in risk factors and diagnosis, a pre-planned subgroup analysis was performed for preschoolers (aged 2--4 years) *versus* school-aged children (aged 5--17 years). Statistical analyses were performed using SPSS (version 25; Chicago, IL, USA), and a two-sided significance level of 0.05 was used. Informed written consent was obtained before participation. The study was approved by the research ethics committee of the Erasmus Medical Center Rotterdam (MEC 2015--709) and adopted by the other hospitals.

Results {#s3}
=======

221 children were recruited into the study: 110 were admitted to the PICU and 111 to the general ward ([figure 1](#F1){ref-type="fig"}). [Table 1](#TB1){ref-type="table"} shows their baseline characteristics.

![Flowchart of study enrolment. SAA: severe acute asthma; PICU: paediatric intensive care unit.](00126-2020.01){#F1}

###### 

Baseline characteristics

                                             **PICU**   **Paediatric ward**   **p-value**               
  ----------------------------------------- ---------- --------------------- ------------- ------------ -------------
  **Subjects**                                 110                                111                   
  **Age years**                                110           8 (5--12)            111        5 (3--7)    **\<0.001**
  **Preschoolers (age 2--4 years)**            110            27 (25)             111        55 (50)     **\<0.001**
  **Male**                                     110            68 (62)             111        69 (62)        0.958
  **Caucasian**                                110            60 (55)             111        79 (71)      **0.011**
  **Asthma diagnosis prior to admission**      110            84 (76)             111        79 (71)        0.380
  **Asthma treated by^\#^**                                                                                 0.370
   General practitioner                         82            29 (35)             77         28 (36)    
   Paediatrician                                82            31 (38)             77         22 (29)    
   Paediatric pulmonologist                     82            22 (27)             77         27 (35)    
  **Steroid naïve**                            110            56 (51)             111        67 (60)        0.157
  **ICS dose^¶^** **μg**                        52            323±181             44         224±102      **0.001**
  **Adherence to ICS^¶^**                                                                               
   PDC %                                        52             73±33              43          62±30         0.114
   PDC ≥80%                                     52            30 (58)             43         16 (37)      **0.047**
  **Born \<37 weeks' gestational age**          84            13 (15)             84         15 (18)        0.679
  **Highest parental education level**                                                                      0.390
   Low                                          82             3 (4)              84          1 (1)     
   Middle                                       82            35 (43)             84         31 (37)    
   High                                         82            44 (54)             84         52 (62)    
  **SES scores^+^**                            110          −0.29±1.36            111       −0.25±1.28      0.824

Data are presented as n, median (interquartile range), n (%) or mean±[sd]{.smallcaps}, unless otherwise stated. Bold type represents statistical significance. PICU: paediatric intensive care unit; ICS: inhaled corticosteroids; PDC: proportion of days covered; SES: socioeconomic status. ^\#^: children with a diagnosis of asthma prior to admission. ^¶^: of the children with prescribed ICS. ^+^: the postal code was used to quantify the neighbourhood SES, with a mean of zero. A lower (negative) score is associated with a lower SES.

Asthma was diagnosed before admission in 76% of the children admitted to the PICU and in 71% of the children admitted to the general ward. The proportion of steroid-naïve children, with or without a previous asthma diagnosis, did not differ significantly between PICU and general ward. Children admitted to the PICU were significantly older. Other significant factors associated with increased odds of PICU admission included being non-Caucasian, ICS adherence, asthma symptoms \>1 week prior to admission and previous PICU admission ([table 2](#TB2){ref-type="table"}). Two children died at the PICU of hypoxic ischaemic encephalopathy following out-of-hospital cardiac arrest, most likely due to patient delay and anaphylaxis.

###### 

Asthma severity

                                                   **PICU**   **Paediatric ward**   **p-value**            
  ----------------------------------------------- ---------- --------------------- ------------- --------- -------------
  **Subjects**                                       110                                111                
  **Medication step prior to admission^\#^**                                                                   0.076
  ** **Step 1                                        110            31 (28)             111       42 (38)  
  ** **Step 2                                        110            12 (11)             111       10 (9)   
  ** **Step 3                                        110            18 (16)             111       24 (22)  
  ** **Step 4                                        110            24 (22)             111       10 (9)   
  ** **Step 5                                        110                                111                
  ** **No medication                                 110            25 (23)             111       25 (23)  
  **Symptoms \>1 week prior to admission**           108            60 (55)             109       25 (23)   **\<0.001**
  **Prior hospital admissions**                                                                            
  ** **Non-PICU                                      106            64 (60)             97        69 (71)      0.107
  ** **Ever to PICU                                  110            15 (14)             111        6 (5)     **0.037**
  ** **Admission in previous year                    108            32 (30)             111       30 (27)      0.669
  **Emergency department visits previous year**                                                              **0.022**
  ** **None                                           84            38 (45)             84        21 (25)  
  ** **1--3                                           84            41 (49)             84        57 (68)  
  ** **\>3                                            84             5 (6)              84         6 (7)   
  **Prednisolone course in the previous year**        84            56 (67)             84        71 (85)    **0.007**

Data are presented as n or n (%), unless otherwise stated. Bold type represents statistical significance. PICU: paediatric intensive care unit. ^\#^: according to the Global Initiative for Asthma \[1\].

The presence of human rhinovirus (HRV), or other viruses, was not a risk factor for PICU admission ([table 3](#TB3){ref-type="table"}).

###### 

Atopy and environmental triggers

                                        **PICU**   **Paediatric ward**   **p-value**            
  ------------------------------------ ---------- --------------------- ------------- --------- -------
  **Subjects**                            110                                111                
  **Allergic sensitisation^\#^**          103            79 (77)             110       71 (65)   0.052
  **Multiple sensitisation^¶^**           102            24 (24)             110       15 (14)   0.063
  **Food allergies**                       56            22 (39)             53        7 (13)     NA
  **Respiratory viral infections**                                                              
   PCR positive for ≥1 virus              102            56 (55)             104       65 (63)   0.268
   PCR positive for ≥2 viruses            102             7 (7)              104       14 (13)   0.191
   Symptoms and PCR positive               98            44 (45)             103       53 (52)   0.352
   PCR positive for rhinovirus            102            42 (41)             104       56 (54)   0.069
    Rhinovirus A                           22            10 (46)             33        17 (52)   0.448
    Rhinovirus B                           22             1 (5)              33           0     
    Rhinovirus C                           22            11 (50)             33        16 (49)  
  **Parental self-reported smoking**      103            28 (27)             108       26 (24)   0.812
  **Urinary cotinine**                                                                           0.150
  ** **Nonsmoker \<10 ng·mL^−1^            96            74 (77)             89        77 (87)  
  ** **Passive smoker \>10 ng·mL^−1^       96            20 (21)             89        12 (13)  
   Active smoker \>200 ng·mL^−1^           96             2 (2)              89                 
  **Siblings \>2**                         84            25 (30)             84        26 (31)   0.867

Data are presented as n or n (%), unless otherwise stated. PICU: paediatric intensive care unit; NA: not available. ^\#^: positive radioallergosorbent test (RAST) = IgE \>0.7 kU·L^−1^ for at least one of the allergens; ^¶^: positive RAST for at least one pet, pollen and house dust mite.

[Table 4](#TB4){ref-type="table"} shows presentation and in-hospital management. The asthma severity scores (Qureshi score) at admission were comparable between groups.

###### 

Presentation and in-hospital management

                                         **PICU**   **Paediatric ward**   **p-value**              
  ------------------------------------- ---------- --------------------- ------------- ----------- -------------
  **Subjects**                             110                                111                  
  **pH^\#^**                               102           7.34±0.1          Not done                
  ***P*~CO~2~~** **kPa^\#^**               102            5.5±1.8          Not done                
  **Asthma severity score (Qureshi)**                                                                  0.439
   Mild                                    105             6 (6)              106         9 (8)    
   Moderate                                105            50 (48)             106        56 (53)   
   Severe                                  105            49 (47)             106        41 (39)   
  **Acute asthma treatment**                                                                       
   Inhaled short-acting β-agonist          110           108 (98)             111       111 (100)      0.154
   Systemic corticosteroids                110           109 (99)             111       110 (99)       0.995
   Antibiotics                             110            45 (41)             110        18 (16)    **\<0.001**
   Intravenous magnesium                   110           108 (98)             111        16 (14)    **\<0.001**
   Intravenous salbutamol                  110           109 (99)             111           0       **\<0.001**
   Ketamine                                110            12 (11)             111           0       **\<0.001**
   Theophylline                            110             7 (6)              111           0       **\<0.001**
  **Maximal respiratory support**                                                                   **\<0.001**
   None                                    110             1 (1)              111        26 (23)   
   Nasal cannula                           110            15 (14)             111        71 (64)   
   Non-rebreathing mask                    110            34 (31)             111        14 (13)   
   High-flow nasal cannula                 110            46 (42)             111                  
   Noninvasive ventilation                 110             1 (1)              111                  
   Invasive mechanical ventilation         110            13 (12)             111                  
  **Disposition**                                                                                  
   Sent home                               110           108 (98)             111       111 (100)  
   Died in the hospital                    110             2 (2)              111           0      
  **Hospital length of stay days**         107            6.3±2.3             111        3.2±1.2    **\<0.001**

Data are presented as n, mean±[sd]{.smallcaps} or n (%), unless otherwise stated. Bold type represents statistical significance. PICU: paediatric intensive care unit; *P*~CO~2~~: carbon dioxide tension. ^\#^: determined in a capillary blood sample.

Multiple logistic regression analysis revealed that a PICU admission was significantly more likely in children who were older, had had symptoms \>1 week prior to admission and were exposed to ETS ([table 5](#TB5){ref-type="table"}).

###### 

Multiple logistic regression analysis of risk factors for paediatric intensive care unit (PICU) admission

                                                    **OR (95% CI)**      **p-value**
  ---------------------------------------------- ---------------------- -------------
  **Steroid naïve**                               1.144 (0.575--2.276)      0.702
  **Age in years^\#^**                            1.263 (1.141--1.399)   **\<0.001**
  **Female**                                      1.407 (0.722--2.745)      0.316
  **Caucasian**                                   0.532 (0.273--1.039)      0.064
  **Respiratory viral infection**                 1.207 (0.601--2.424)      0.597
  **Symptoms \>1 week prior to admission**        4.252 (2.130--8.489)   **\<0.001**
  **Previous PICU admissions**                    2.785 (0.873--8.879)      0.083
  **Positive urinary cotinine \>10 ng·mL^−1^**    3.733 (1.442--9.659)    **0.007**

Bold type represents statistical significance. ^\#^: continuous variable.

Preschool children admitted to a PICU were less often treated by a paediatric pulmonologist prior to admission than children in the general ward group ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials)).

In school-aged children, significant factors associated with increased odds of PICU admission included being non-Caucasian, an older age, presence of symptoms \>1 week prior to admission, and high urinary cotinine (all p-values \<0.017; [supplementary table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials)). In multiple logistic regression analysis, an older age, symptoms \>1 week prior to admission and elevated cotinine remained statistically significant predictors of PICU admission ([supplementary table S3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00126-2020.figures-only#fig-data-supplementary-materials)).

Discussion {#s4}
==========

In this nationwide multicentre prospective study, we found no significant difference in the proportion of steroid-naïve children with SAA admitted to a PICU or a general ward. In general, PICU children were older, more exposed to tobacco smoke and had a longer duration of asthma symptoms before admission.

Daily ICS or ICS as rescue medication with a short-acting β-agonist (SABA) protects against asthma exacerbations compared to SABA alone \[[@C17], [@C30]\], but uncontrolled asthma is not rare \[[@C31]\], even in children with daily ICS, and was a risk factor for PICU admission in some studies \[[@C2], [@C7]\]. This might be due to the fact that children using ICS had persistent and more severe asthma and consequently a higher risk for SAA and PICU admission. This theory is supported by the fact that children admitted to the PICU had a significantly higher ICS dose prior to admission. In our study, risk factors for PICU admission seem to be driven by host (age, ethnic background and patient delay) and environmental (exposure to ETS) characteristics, rather than ICS use only. Targeted strategies aimed at the prevention of severe asthma exacerbations, even despite treatment with daily ICS, are needed. Strategies such as enhancing awareness in the general population of symptoms of asthma or uncontrolled asthma may empower the general public to seek medical help earlier than some parents in this study. The risk of children having dangerous asthma exacerbations as a result of cigarette smoke exposure is yet another clear effect of cigarette smoke exposure that legislatures need to take into account in smoke-free policies.

The most important risk factor for PICU admission was having symptoms for \>1 week prior to admission. These children were significantly older (median age 8 years *versus* 6 years). Only 30% of the children with symptoms for \>1 week prior to admission received oral corticosteroids (OCS) before arrival at the emergency department. Patient and doctor delay contributed to a longer duration of symptoms followed by a more severe attack. Early treatment with OCS in these children could have possibly prevented hospitalisation or PICU admission. Hospital admission produces a high level of stress on the child and caregivers, especially at the PICU. Furthermore, bed availability and the high medical costs emphasise the need for a more vigilant approach if symptoms persist to prevent PICU admission.

The age difference between the PICU and general ward group could be due to the fact that these groups represent different disease categories. S[tein]{.smallcaps} and M[artinez]{.smallcaps} \[[@C32]\] have shown that asthma phenotypes are markedly heterogeneous in the first 6 years of life. In fact, some of these phenotypes are transient and seem to behave idiosyncratically.

In agreement with previous studies, exposure to ETS was significantly associated with a higher frequency of PICU admission \[[@C2]\] or emergency department management failure \[[@C33]\]. In the PICU population, children with ETS-associated SAA deteriorated and recovered more slowly than non-ETS-exposed children \[[@C34]\]. Additional to previous studies we used urinary cotinine to quantify and identify ETS as an objective risk factor for PICU admission among children hospitalised for SAA. Caregivers should be made aware that ETS confers a four-fold increased risk for PICU admission in case of SAA, and offered appropriate support to stop smoking. Preferably, any financial obstacles should be reimbursed.

Our data corroborate previous studies reporting that the majority of children requiring hospital admission were allergically sensitised and had at least one viral respiratory infection identified, mostly due to rhinovirus \[[@C2], [@C13], [@C15], [@C35]--[@C38]\]. In our study, HRV-C was not a risk factor for PICU admission among children hospitalised for asthma. Although we found a high HRV-C prevalence, in itself it may be a risk factor for hospitalisation, but not differentiate in terms of severity beyond that point.

Children with SAA admitted to Dutch PICUs have a relatively short PICU stay compared with the general PICU population. According to the Dutch paediatric guideline for SAA \[[@C21]\], continuous *i.v.* administration of salbutamol requires immediate transfer to a PICU, regardless of the dosage. Hence, children in our study might have had less severe illness than asthmatic children in other PICU studies, as suggested by the low numbers of children requiring invasive mechanical ventilation and low mortality \[[@C2]\].

Of the children admitted to the PICU, 24% were first presentations. Hence in these children a PICU admission could not easily have been prevented except for education of the general public on asthma symptoms.

In addition, we looked at the effect of polymorphisms of the *ADRβ2* and *CDHR3* asthma risk alleles, since the *ADRβ2* gene might reduce bronchodilator responsiveness in asthmatic children \[[@C39]\], and the *CDHR3* asthma risk allele is associated with more severe HRV-C-induced asthma attacks \[[@C40]\]. In our study, genotyping of the *ADRβ2* at position 16 (rs1042713) and 27 (rs1042714), and the *CDHR3* asthma risk allele (rs6967330) showed no significant differences between PICU and general ward (data not shown). However, our study was not powered to detect a difference.

Limitations/strengths {#s4a}
---------------------

Strengths of the present study are a high inclusion rate of 75% of children admitted to all Dutch PICUs, with standardised criteria for PICU admission. We investigated multiple potential risk factors, including objective measures such as cotinine in the urine for exposure to ETS, RT-PCR for viral infections, and use of asthma medication based on pharmacy records. There are some limitations as well. First, asthma was defined as diagnosed by a paediatrician prior to or during the exacerbation. The diagnosis was reviewed by a paediatric pulmonologist at the follow-up visits. We are well aware that asthma may be undistinguishable from acute viral wheeze in children aged \<6 years; however, this will not affect treatment decisions in the setting of SAA. All children were seen by a paediatric pulmonologist during follow-up and 90% still used asthma medication after 3--9 months (the remaining 10% were lost to follow-up), which supports that the initial asthma diagnosis was correct. Second, data regarding lung function at time of presentation to the emergency department are lacking. Only 20 (18%) children in the PICU group had performed lung function testing recently: 13 children had airflow obstruction, nine children had forced expiratory volume in 1 s (FEV~1~) \<80%. In the general ward group, 10 (9%) children performed a lung function test prior to admission: three children had airflow obstruction, with a FEV~1~ \<80% in one child. Third, we used the PDC in the period preceding the index admission as a proxy for ICS treatment. Although the PDC is an objective measurement, this is not equivalent to the actual use of medication or good inhalation technique. Lastly, 30% of DNA analysis is missing in the general ward group because blood samples were only collected if blood was drawn for routine care measurements.

Conclusion {#s4b}
----------

We found no significant differences in the proportion of steroid-naïve children between children with SAA admitted to the PICU *versus* those admitted to a general ward. Prolonged duration of symptoms prior to admission and environmental tobacco smoke exposure were clinically relevant strong risk factors for PICU admission. These are preventable triggers and our data clearly support the call for smoking cessation by caretakers of children. We recommend a rapid and vigilant approach for children with prolonged asthma symptoms as they are at high risk for PICU admission for SAA.
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